Rosuvastatin Inhibits MMP-2 Expression and Limits the Progression of Atherosclerosis in LDLR-deficient Mice

Archives of Medical Research

Volumn 40, Issue 5, 2009, Pages 345-351

  Guo, Hangyuan ^a,b   Shi, Yafei ^b   Liu, Longbin ^a   Sun, Aijing ^a   Xu, Fukang ^a   Chi, Jufang ^a  

^a SHAOXING PEOPLE S HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; ZYMOGRAPHY;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CHOLESTEROL; FLUOROBENZENES; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; PYRIMIDINES; RECEPTORS, LDL; SULFONAMIDES; TRIGLYCERIDES;

EID: 70349114600     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.07.006     Document Type: Article

References (24)

1. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
2. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
3. Kuzuya M., and Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 10 (2003) 275-282
4. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
5. Choudhury R.P., Carrelli A.L., Stern J.D., et al. Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J Vasc Res 41 (2004) 75-83
6. Wang Y.X., Martin-McNulty B., Huw L.Y., et al. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis 162 (2002) 23-31
7. Chen J., Li D., Schaefer R., et al. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 184 (2006) 295-301
8. Delsing D.J., Jukema J.W., van de Wiel M.A., et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 42 (2003) 63-70
9. Riccioni G., Bazzano L.A., Bucciarelli T., et al. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study. Expert Opin Pharmacother 9 (2008) 2403-2408
10. Luan Z., Chase A.J., and Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23 (2003) 769-775
11. Cheng X.W., Kuzuya M., Sasaki T., et al. Green tea catechins inhibit neointimal hyperplasia in a rat carotid arterial injury model by TIMP-2 overexpression. Cardiovasc Res 62 (2004) 594-602
12. Ross R., and Agius L. The process of atherogenesis: cellular and molecular interaction: from experimental animal models to humans. Diabetologia 35 Suppl 2 (1992) S34-S40
13. Pasterkamp G., Schoneveld A.H., Hijnen D.J., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
14. Li Z., Li L., Zielke H.R., et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 148 (1996) 121-128
15. Galis Z.S., Johnson C., Godin D., et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration arterial remodeling and geometrical. Circ Res 91 (2002) 852-859
16. Singh B.M., and Mehta J.L. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 163 (2003) 1296-1304
17. Rouis M., Adamy C., Duverger N., et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 100 (1999) 533-540
18. Faia K.L., Davis W.P., Marone A.J., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: correlation with in-situ zymography. Atherosclerosis 160 (2002) 325-337
19. Chen J., Li D., Schaefer R.F., et al. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 44 (2004) 446-452
20. Ajith T., Riji T., and Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 35 (2008) 625-629
21. Muchova L., Wong R.J., Hsu M., et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 85 (2007) 800-810
22. Libby P., Bonow R.O., Mann D.L., et al. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (2007), WB Saunders, Philadelphia
23. Schreyer S.A., Lystig T.C., Vick C.M., et al. Mice deficient in apolipoprotein E but not LDL receptors are resistant to accelerated atherosclerosis associated with obesity. Atherosclerosis 171 (2003) 49-55
24. MacDonald M.L., Singaraja R.R., Bissada N., et al. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J Lipid Res 49 (2008) 217-229